Tepmetko 225 mg
Tepmetko 225 mg is a medicine authorised by Swissmedic under authorisation number 68113. The authorisation holder is Merck (Schweiz) AG. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 22 June 2021 and the authorisation is limited until 14 December 2028. ATC code L01EP02 places the medicine in the group Antineoplastic agents.
| Authorisation number | 68113 |
|---|---|
| Name | Tepmetko 225 mg |
| Full name | Tepmetko 225 mg, Filmtabletten |
| Authorisation holder | Merck (Schweiz) AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01EP02 |
| First authorisation | 22 June 2021 |
| Authorisation validity | 14 December 2028 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Tepmetko 225 mg, Filmtabletten | A | 22 June 2021 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 60 | Tablette(n) | L01EP02 | 07.16. | A |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Tepmetko 225 mg authorised in Switzerland?
Yes. Tepmetko 225 mg is authorised by Swissmedic under authorisation number 68113, data as of 01 September 2026. The authorisation is limited until 14 December 2028.
Which dispensing category does Tepmetko 225 mg have?
Tepmetko 225 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Tepmetko 225 mg?
The authorisation holder is Merck (Schweiz) AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.